2 Result: Argenx
Medical Breakthroughs: argenx's VYVGART Hytrulo and Pfizer's TALZENNA Garner FDA Approval
June 21st, 2023
argenx SE (Nasdaq: ARGX) has received approval from the U.S. Food and Drug Administration (FDA) for VYVGART Hytrulo, a subcutaneous injection used to treat generalized myasthenia gravis (gMG) in adult patients who test positive for anti-acetylcholine. Read more
Akebia Therapeutics, MDxHealth, Avis Budget, argenx, Five9, Inventiva: Analyst Upgrades and Initiations Point to Potential Upsides
May 31st, 2023
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company, received an upgrade from Neutral to Overweight by Piper Sandler, with the price target raised from $2 to $4. On Wednesday, $AKBA closed at $1.04, indicating a potential u. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025
Member Login